Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
Analysts have mixed opinions on Biomarin Pharmaceutical (NASDAQ:BMRN) with recent ratings showing a range from somewhat bullish to indifferent. The average 12-month price target has decreased by 1.2% to $99.67. Key analysts have adjusted their ratings and price targets, reflecting varied sentiments about the company's future performance.
June 27, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed opinions on Biomarin Pharmaceutical with recent ratings showing a range from somewhat bullish to indifferent. The average 12-month price target has decreased by 1.2% to $99.67. Key analysts have adjusted their ratings and price targets, reflecting varied sentiments about the company's future performance.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on BMRN's stock price. While some analysts are optimistic, others have lowered their expectations, leading to an overall balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100